CalciMedica Announces Private Placement Financing for Up to Approximately $49 Million to Advance Pulmonary Hypertension Program
CalciMedica Announces Clinical Development of Auxora May Proceed Following FDA Review of KOURAGE Trial Interim Safety Data
CalciMedica Reports First Quarter 2026 Financial Results and Provides Clinical & Corporate Updates
CalciMedica Reports 2025 Financial Results and Provides Clinical Updates
CalciMedica Pauses Kidney Study, Eyes New Trial In Pancreatitis
CalciMedica Announces Discontinuation of Phase 2 KOURAGE Trial in AKI Following Independent Data Monitoring Committee Recommendation
Airbus Clinches Contract to Supply 30 A320neo Aircraft to CALC
CalciMedica (NASDAQ:CALC) Trading Down 2.1% – Time to Sell?
CalciMedica Reports Third Quarter 2025 Financial Results and Provides Clinical & Corporate Updates
CalciMedica Announces Publication in JCI Insight of Preclinical Data Supporting CRAC Channel Inhibitor as a Potential Therapy for Pulmonary Arterial Hypertension
CalciMedica Presents Data from Preclinical Study of Auxora™ in an Animal Model of AKI at ASN Kidney Week 2025
CalciMedica and Telperian Announce Collaboration to Integrate Innovative Artificial Intelligence Engine to Analysis of Clinical Trials of Auxora™
CalciMedica to Participate in the H.C. Wainwright 27th Annual Global Investment Conference
CalciMedica Reports Second Quarter 2025 Financial Results and Provides Clinical & Corporate Updates
CalciMedica to Participate in the H.C. Wainwright 4th Annual Kidney Virtual Conference
CalciMedica Announces Publication in the American Journal of Nephrology Discussing Design and Rationale of Phase 2 KOURAGE Trial of Auxora™ in AKI with Respiratory Failure
CalciMedica Announces Upcoming Symposium at the 43rd Vicenza Course AKI-CRRT-EBPT and Critical Care Nephrology Meeting
CalciMedica Reports First Quarter 2025 Financial Results and Provides Clinical & Corporate Updates
CalciMedica Announces Presentations at Upcoming Medical Meetings
CalciMedica Inc. (CALC) Moves to Buy: Rationale Behind the Upgrade
CalciMedica to Participate in the Jones Healthcare and Technology Innovation Conference
CalciMedica Reports 2024 Financial Results and Provides Clinical & Corporate Updates
CalciMedica Secures Credit Facility for Up to $32.5 Million
CalciMedica Presents AKI Data from a Post-Hoc Analysis of the Phase 2 CARDEA trial of Auxora™ in Severe COVID-19 Pneumonia at the 30th International AKI & CRRT Conference
CalciMedica Announces Upcoming Plenary Presentation at the 30th International AKI & CRRT Conference
CalciMedica to Participate in the Oppenheimer 35th Annual Healthcare Life Sciences Conference
CalciMedica Announces Appointment of Dr. Alan Glicklich to Board of Directors
CalciMedica to Participate in the Piper Sandler 36th Annual Healthcare Conference
CalciMedica Announces Presentations at Upcoming Medical Meetings
CalciMedica Reports Third Quarter 2024 Financial Results and Provides Clinical & Corporate Updates
CalciMedica Strengthens Leadership Team with Appointment of Stephen Bardin as Chief Financial Officer
CalciMedica Announces Pricing of Public Offering of Common Stock
CalciMedica Announces Proposed Public Offering of Common Stock
CalciMedica to Present Late-Breaking Positive Data, Including a Win Ratio Analysis, from Phase 2b CARPO Trial of Auxora™ in Acute Pancreatitis (AP) at the American College of Gastroenterology (ACG) 2024 Annual Scientific Meeting
CalciMedica to Host a Call to Review Full Data Set, including a Win Ratio Analysis, from Phase 2b CARPO Trial of Auxora™ in Acute Pancreatitis (AP)
CalciMedica Announces Upcoming Late-Breaker Plenary Presentation at the American College of Gastroenterology (ACG) 2024 Annual Scientific Meeting
CalciMedica to Present at the H.C. Wainwright 26th Annual Global Investment Conference
CalciMedica Reports Second Quarter 2024 Financial Results and Provides Clinical & Corporate Updates
Does CalciMedica Inc. (CALC) Have the Potential to Rally 232.3% as Wall Street Analysts Expect?
CalciMedica Announces First Patient Enrolled in Phase 2 KOURAGE Trial of Auxora™ in Severe Acute Kidney Injury (AKI)
CalciMedica Announces Presentations at Two Upcoming Healthcare Investment Conferences
CalciMedica Set to Join Russell Microcap® Index
CalciMedica Announces Positive Topline Data from Phase 2b CARPO Trial of Auxora™ in Acute Pancreatitis (AP)
CalciMedica to Host Conference Call to Review Topline Data from Phase 2b CARPO Trial of Auxora™ in Acute Pancreatitis (AP)
3 Massively Undervalued 10-Bagger Stocks to Buy
CalciMedica Reports First Quarter 2024 Financial Results and Provides Clinical & Corporate Updates
CalciMedica Announces Upcoming Presentation at Digestive Disease Week 2024
CalciMedica Announces Last Patient Enrolled in Phase 2b CARPO Trial of Auxora™ in Acute Pancreatitis
CalciMedica Reports 2023 Financial Results and Provides Clinical & Corporate Updates
CalciMedica Presents Data from Preclinical Studies of Auxora in Acute Kidney Injury at the 29th International AKI & CRRT Conference